Blue Cross Blue Shield/Blue Care Network of Michigan
Medication Authorization Request Form

Blue Cross Blue Shield Blue Care Network of Michigan

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION		PHYSICIAN INFORMATION
Name		**Name**
ID Number		**Specialty**
D.O.B.	☐Male ☐Female	**Address**
Diagnosis		**City /State/Zip**
Drug Name	**Herceptin Hylecta**	**Phone:** **Fax:**
Dose and Quantity		**NPI**
Directions		**Contact Person**
Date of Service(s)		**Contact Person** **Phone / Ext.**

STEP 1: DISEASE STATE INFORMATION

Required Demographic Information:

Patient Weight: _____*kg*

*Patient Height:*_____*ft* _____*inches*

Will the provider be administering the medication to the FEP member within the health plan's geographic service area?

❑ Yes ❑ No *If No, a prior authorization is not required through this process*.

Prior authorizations are required for FEP members that will be serviced by a provider within the health plan's geographic service area. If you are not a provider in the geographic service area, please contact the health plan for questions regarding the FEP member's benefit requirements.

Is this member's FEP coverage primary or secondary coverage?

❑ If primary, continue with question set.

❑ If secondary, **an authorization is not needed through this process. Please contact the member's primary coverage for determination of benefit and additional information.**

Criteria Questions:

1. What is the patient's diagnosis?
   - ❑ HER-2 overexpressing breast cancer
   - ❑ Other diagnosis ***(please specify)***:_____

2. Does the prescriber agree to monitor for cardiac function and pulmonary toxicity? ❑Yes ❑No

3. **FEMALE Patient**: Is the patient of reproductive potential? ❑Yes* ❑No

   If YES, will the patient be advised to use effective contraception during treatment with Herceptin Hylecta and for 7 months after the last dose? ❑Yes ❑No

   MALE Patient: Does the patient have a female partner of reproductive potential? ❑Yes* ❑No

   If YES, will the patient be advised to use effective contraception during treatment with Herceptin Hylecta and for 7 months after the last dose? ❑Yes ❑No

4. Has the patient been on Herceptin Hylecta continuously for the last **6 months** excluding samples? ❑Yes ❑No
Please select the answer below:

❑No – this is **INITIATION** of therapy, please answer the following questions:

a. Has HER-2 protein overexpression or HER-2 gene amplification been confirmed by an FDA-approved test? ❑Yes ❑No

b. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to one of the preferred medications: Kanjinti, Ogivri, or Ontruzant? ❑Yes ❑No

❑Yes – this is a PA renewal for **CONTINUATION** of therapy.

Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review **(required)**

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

☐ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	**Physician Signature**	**Date**
Step 2: Checklist	☐ Form Completely Filled Out ☐ Provide chart notes	☐ Attach test results
Step 3: Submit	**By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979**	**By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320**